AbbVie Inc. closed $6.12 short of its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...

According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

This includes rimegepant, which is sold by U.S. pharma giant Pfizer under the brand name Vydura, and ubrogepant, sold as ...

North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...